Epicenter,
I believe Dr. Pamukcu stated that they have not seen any toxic
effects on tissue other than the neoplastic type. A quote from the
latest release hints at this:
"''Exisulind acts via a mechanism we began to uncover several years ago. This mechanism involves a previously undescribed phosphodiesterase (PDE) that specifically degrades cyclic GMP (cGMP), similar to members of the PDE5 gene family. This new PDE, which is the subject of additional pending patent applications, is involved in regulating apoptosis in neoplastic (precancerous and cancerous) cells,'' said Rifat Pamukcu, M.D., chief scientific officer at Cell Pathways.
Further on, Dr. Joe Thompson states:
"Dr. Thompson added, ''Targeting the new cGMP-PDE, our research group has discovered compounds that have up to 20,000 times the apoptotic potency of exisulind. Like exisulind, these new compounds affect neoplastic cells without inducing apoptosis in normal cells in cell culture."
Frankly, things look promising IMO. So far I can't see anything
wrong here. Publication in a peer reviewed journal will help clear
this up. Don't know what tomorrow will bring, CNBC could be very
positive or could be negative due to the small initial patient
population for APC and Prevatac. We'll see...
Bob |
